中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 8
Aug.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(8): 1831-1837

Effectiveness and safety of coblopasvir hydrochloride combined with sofosbuvir in treatment of chronic hepatitis C

DOI: 10.12449/JCH260815

  • Department of Infectious Diseases，Maanshan Fourth People’s Hospital，Maanshan，Anhui 243000，China

More Information
  • Corresponding author: Wei Ming， 10287008@qq.com （ORCID： 0009-0000-8725-7682）
  • Received Date: 2026-01-04
  • Accepted Date: 2026-04-27
  • Published Date: 2026-08-25
    Abstract
  •   Objective  To investigate the effectiveness and safety of coblopasvir hydrochloride combined with sofosbuvir （CLP/SOF） in the treatment of patients with chronic hepatitis C （CHC） and those with genotype 3b in terms of virologic response rate， changes in liver and renal function parameters， and adverse events， and to provide a reference for clinical diagnosis and treatment.  Methods  The patients with CHC who were admitted to Maanshan Fourth People’s Hospital from March 1， 2023 to July 31， 2024 were enrolled and treated with CLP/SOF for a course of 12 weeks. Follow-up assessments were conducted at weeks 4， 8， and 12 of treatment and at 12 weeks after the end of treatment， and related data were collected， including HCV RNA， routine blood test results， and liver and renal function parameters. Sustained virologic response at 12 weeks after treatment （SVR12） and safety profile were evaluated. The Friedman test was used for comparison of liver and renal function parameters， routine blood test results， and liver fibrosis score at different time points.  Results  A total of 107 CHC patients treated with CLP/SOF were enrolled， with an age of 22 — 92 years， and there were 55 male patients. The predominant genotypes were 1b （46.73%） and 3b （28.97%）. Comorbidities mainly included liver cirrhosis （15 patients）， fatty liver disease （27 patients）， syphilis （15 patients）， HBV infection （8 patients）， and HIV infection （2 patients）. The overall SVR12 rate was 100% （107/107）， with an SVR12 rate of 100% for subgroups with different genotypes and those with liver cirrhosis， fatty liver disease， syphilis， HBV infection， or HIV infection. The patients with HCV genotype 3b comorbid with liver cirrhosis， fatty liver disease， syphilis， HBV infection， hypertension or diabetes also achieved an SVR12 rate of 100%. After CLP/SOF treatment， the patients showed significant reductions in the levels of the liver function parameters alanine aminotransferase， aspartate aminotransferase， total bilirubin， and hemoglobin （all P<0.001） and significant reductions in the liver fibrosis scores fibrosis-4 and aspartate aminotransferase-to-platelet ratio index （both P<0.001）. The median creatinine level was 66 μmol/L before treatment， which decreased to 52 μmol/L at week 12 of treatment （P<0.001）. No adverse events were reported.  Conclusion  Patients with CHC achieve a high SVR12 rate and significant improvements in liver function parameters and liver fibrosis markers after treatment with the CLP/SOF regimen， and this regimen has no significant impact on renal function and shows a favorable safety profile. Therefore， it holds promise for clinical application.

     

    • FullText(HTML)
  • loading
    • References(26)
  • [1]
    World Health Organization. Global hepatitis report 2024: Action for access in low- and middle-income countries[EB/OL].( 2024-04-09)[ 2025-12-23]. https://www.who.int/publications/i/item/9789240091672. https://www.who.int/publications/i/item/9789240091672
    [2]
    Martinello M, Solomon S S, Terrault N A, et al. Hepatitis C[J]. Lancet, 2023, 402( 10407): 1085- 1096. DOI: 10.1016/S0140-6736(23)01320-X.
    [3]
    World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection[EB/OL].( 2018-07-01)[ 2025-12-23]. https://www.who.int/publications/i/item/9789241550345. https://www.who.int/publications/i/item/9789241550345
    [4]
    Trickey A, Artenie A, Feld J J, et al. Estimating the annual number of hepatitis C virus infections through vertical transmission at country, regional, and global levels: A data synthesis study[J]. Lancet Gastroenterol Hepatol, 2025, 10( 10): 904- 914. DOI: 10.1016/S2468-1253(25)00189-X.
    [5]
    Chevaliez S, Hézode C, Soulier A, et al. High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype(SYREN trial)[J]. Gastroenterology, 2011, 141( 1): 119- 127. DOI: 10.1053/j.gastro.2011.03.039.
    [6]
    Polaris Observatory Collaborators. Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies[J]. J Hepatol, 2025, 83( 2): 329- 347. DOI: 10.1016/j.jhep.2025.01.013.
    [7]
    Gao Y H, Kong F, Li G M, et al. Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial[J]. Liver Int, 2020, 40( 11): 2685- 2693. DOI: 10.1111/liv.14633.
    [8]
    Rao H Y, Song G J, Li G M, et al. Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis[J]. J Viral Hepat, 2020, 27( 1): 45- 51. DOI: 10.1111/jvh.13208.
    [9]
    Ruan L M, Zhang X C, Zhang X Y, et al. Real-world effectiveness and safety of coblopasvir plus sofosbuvir in the treatment of chronic hepatitis C infection in Wenzhou, Eastern China: A multicenter observational study[J]. J Clin Transl Hepatol, 2026, 14( 3): 358- 361. DOI: 10.14218/JCTH.2025.00673.
    [10]
    Yan L, Wubuliaishan M, Kou X N, et al. Efficacy and safety of 12-week coblopasvir/sofosbuvir regimen for hepatitis C in northwest China: A multi-center prospective study[J]. J Med Virol, 2026, 98( 5): e70978. DOI: 10.1002/jmv.70978.
    [11]
    Lu Yulian. Clinical efficacy and safety of sofosbuvir combined with coblopasvir in patients with HCV/HIV co-infection[J]. J China Prescription Drug, 2025, 23( 20): 88- 92. DOI: 10.3969/j.issn.1671-945X.2025.20.021.

    陆玉莲. 索磷布韦联合可洛派韦治疗HCV/HIV共感染患者的临床疗效与安全性[J]. 中国处方药, 2025, 23( 20): 88- 92. DOI: 10.3969/j.issn.1671-945X.2025.20.021.
    [12]
    Mou Chunyan, Xu Danqing, Mu Huan, et al. Efficacy and safety of coblopasvir hydrochloride capsules/sofosbuvir tablets with or without ribavirin tablets in treatment of patients with chronic hepatitis C virus infection[J]. J Clin Hepatol, 2025, 41( 9): 1779- 1787. DOI: 10.12449/JCH250912.

    牟春燕, 许丹青, 木唤, 等. 盐酸可洛派韦和索磷布韦联合或不联合利巴韦林治疗慢性HCV感染者的效果和安全性分析[J]. 临床肝胆病杂志, 2025, 41( 9): 1779- 1787. DOI: 10.12449/JCH250912.
    [13]
    Zhang Yingyuan, Mu Huan, Xu Danqing, et al. Efficacy and safety of coblopasvir hydrochloride combined with sofosbuvir in treatment of patients with genotype 3 hepatitis C virus infection[J]. J Clin Hepatol, 2025, 41( 6): 1075- 1082. DOI: 10.12449/JCH250612.

    张映媛, 木唤, 许丹青, 等. 盐酸可洛派韦联合索磷布韦治疗基因3型HCV感染者的效果及安全性分析[J]. 临床肝胆病杂志, 2025, 41( 6): 1075- 1082. DOI: 10.12449/JCH250612.
    [14]
    Li Yan, Du Junni, Tian Chenhui, et al. Cost-utility analysis of coblopasvir plus sofosbuvir versus sofosbuvir/velpatasvir for treatment of chronic hepatitis C[J]. Chin J Hosp Pharm, 2026, 46( 5): 557- 564. DOI: 10.13286/j.1001-5213.2026.05.11.

    李艳, 杜珺妮, 田晨惠, 等. 可洛派韦联合索磷布韦对比索磷布韦维帕他韦治疗慢性丙型肝炎的成本-效用分析[J]. 中国医院药学杂志, 2026, 46( 5): 557- 564. DOI: 10.13286/j.1001-5213.2026.05.11.
    [15]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline for the prevention and treatment of hepatitis C(2022 version)[J]. Chin J Clin Infect Dis, 2022, 15( 6): 428- 447. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.002.

    中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J]. 中华临床感染病杂志, 2022, 15( 6): 428- 447. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.002.
    [16]
    Zhang Wei, Zhai Song, Du Hong, et al. Efficacy and safety of the 12-week sofosbuvir-coblopasvir regimen in treatment of chronic hepatitis C[J]. J Clin Hepatol, 2023, 39( 3): 539- 545. DOI: 10.3969/j.issn.1001-5256.2023.03.009.

    张伟, 翟嵩, 杜虹, 等. 12周索磷布韦联合可洛派韦治疗慢性丙型肝炎的效果和安全性分析[J]. 临床肝胆病杂志, 2023, 39( 3): 539- 545. DOI: 10.3969/j.issn.1001-5256.2023.03.009.
    [17]
    Flisiak R, Zarębska-Michaluk D, Berak H, et al. Treatment of the most difficult-to-cure hepatitis C virus-infected population with sofosbuvir/velpatasvir[J]. Pol Arch Intern Med, 2024, 134( 2): 16644. DOI: 10.20452/pamw.16644.
    [18]
    Yilihamu Abulitifu, Lian Jiangshan, Remila Bali, et al. Efficacy and safety of Sofosbuvir/Velpatasvir or combined with Ribavirin in treatment of patients with hepatitis C related cirrhosis in Xinjiang region[J]. Chin J Clin Infect Dis, 2022, 15( 6): 459- 463. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.005.

    依力哈木·阿不力提甫, 连江山, 热米拉·巴力, 等. 索磷布韦/维帕他韦单用或联合利巴韦林治疗新疆地区丙型肝炎肝硬化患者的疗效及安全性分析[J]. 中华临床感染病杂志, 2022, 15( 6): 459- 463. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.005.
    [19]
    Yang T T, Chen Q X, Li D D, et al. High prevalence of syphilis, HBV, and HCV co-infection, and low rate of effective vaccination against hepatitis B in HIV-infected patients in West China hospital[J]. J Med Virol, 2018, 90( 1): 101- 108. DOI: 10.1002/jmv.24912.
    [20]
    Zhang Ling, Lin Changfeng, Sun Xia, et al. Etiological detection and epidemiological analysis of 147 syphilis patients with hepatitis C[J]. Infect Dis Inf, 2021, 34( 3): 258- 260, 269. DOI: 10.3969/j.issn.1007-8134.2021.03.014.

    张玲, 林昌锋, 孙霞, 等. 147例梅毒合并丙型肝炎患者病原学检测及流行病学分析[J]. 传染病信息, 2021, 34( 3): 258- 260, 269. DOI: 10.3969/j.issn.1007-8134.2021.03.014.
    [21]
    Hernández-Pliego A, Vergara-Ortega D N, Herrera-Ortíz A, et al. IL-10 and IL-17 as progression markers of syphilis in people living with HIV: A systematic review[J]. Biomolecules, 2022, 12( 10): 1472. DOI: 10.3390/biom12101472.
    [22]
    Comarmond C, Lorin V, Marques C, et al. TLR9 signalling in HCV-associated atypical memory B cells triggers Th1 and rheumatoid factor autoantibody responses[J]. J Hepatol, 2019, 71( 5): 908- 919. DOI: 10.1016/j.jhep.2019.06.029.
    [23]
    Blasczyk H, Bremer W, Phelps C C, et al. A liver-infiltrating CD4+ Tfh1 cell response predicts HCV control, hepatitis, and seroconversion during acute infection[J]. J Clin Invest, 2025, 135( 21): e178089. DOI: 10.1172/JCI178089.
    [24]
    Amernia B, Moosavy S H, Banookh F, et al. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran[J]. BMC Gastroenterol, 2021, 21( 1): 453. DOI: 10.1186/s12876-021-02038-3.
    [25]
    Parikh N D, Mehta M, Tapper E B. FIB-4 and APRI for cirrhosis detection in a privately insured national cohort[J]. JHEP Rep, 2024, 6( 1): 100925. DOI: 10.1016/j.jhepr.2023.100925.
    [26]
    Luo T, Lin Z S, Wu Z X, et al. Trends and associated factors of HIV, HCV and syphilis infection among different drug users in the China-Vietnam border area: An 11-year cross-sectional study(2010-2020)[J]. BMC Infect Dis, 2023, 23( 1): 575. DOI: 10.1186/s12879-023-08239-3.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (11) PDF downloads(1) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return